Cancer Research UK, NCI funding Ras research

Cancer Research UK and the Cancer Research Technology Pioneer Fund will commit £2.5 million ($3.1 million) to collaborate with the National Cancer Institute on research of inhibitors of Ras, long considered an important yet "undruggable" target to treat cancer.

The investment will fund a new preclinical research collaboration between the RAS Initiative at NCI’s Frederick National Laboratory for Cancer Research, led by Frank McCormick, and the Drug Discovery Unit at the Cancer Research UK Beatson Institute, led by Martin Drysdale. Researchers plan to develop and test new molecules to target Ras, as well as screens and assays to identify potential drug candidates...